{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-019498","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.533084+00:00","generated_at":"2026-05-25T18:51:39.889710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track","bullets":["Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.","Completed GRAND CANYON enrollment (175 adults) for sevasemten in Becker; topline data expected Q4 2026.","Positive Phase 2 CANYON topline results for sevasemten in Becker; plan to discuss FDA filing in H1 2025.","On track to report CIRRUS-HCM Phase 2 data in Q1 2025 and LYNX/FOX Duchenne data in H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-019498","json":"https://secwatch.observer/filing/0001104659-25-019498.json","markdown":"https://secwatch.observer/filing/0001104659-25-019498.md","text":"https://secwatch.observer/filing/0001104659-25-019498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/0001104659-25-019498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T18:51:39.889710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}